<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">ISRADIPINE</span><br/>(is-ra'di-peen)<br/><span class="topboxtradename">DynaCirc, </span><span class="topboxtradename">DynaCirc CR<br/></span><b>Classifications:</b> <span class="classification">cardiovascular agent</span>; <span class="classification">calcium channel blocker</span><br/><b>Prototype: </b>Nifedipine<br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>2.5 mg, 5 mg capsules; 5 mg, 10 mg sustained release tablets</p>
<h1><a name="action">Actions</a></h1>
<p>Inhibits calcium ion influx into cardiac muscle and smooth muscle without changing calcium concentrations, thus affecting
         contractility.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Isradipine relaxes coronary vascular smooth muscle with little or no negative inotropic effect. It significantly decreases
         systemic vascular resistance and reduces BP at rest and during isometric and dynamic exercise.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Mild to moderate hypertension.</p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>Angina, CHF.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to isradipine.</p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Patients with CHF, pregnancy (category C), and lactation. Safety and effectiveness in children are not established.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Hypertension</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 1.2510 mg b.i.d. (max: 20 mg/d); DynaCirc CR dosed q.d.<br/><br/><span class="indicationtitle">Angina</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 2.57.5 mg t.i.d. (max: 15 mg/d)<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Do not crush sustained release form. It must be swallowed whole.</li>
<li>
            				Note: After the first 24 wk of therapy, dose may be increased for improved BP control in increments of 5 mg/d at 24
            wk intervals up to a maximum dose of 20 mg/d.
            			
         </li>
<li>Store in tight, light-resistant container.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">CNS:</span> Headache, dizziness, fainting, fatigue, sleep disturbances, vertigo. <span class="typehead">CV:</span> Flushing, ankle edema, palpitations, tachycardia, hypotension, chest pain, CHF. <span class="typehead">GI:</span> Nausea, vomiting, abdominal discomfort, constipation, increased liver enzymes. <span class="typehead">Respiratory:</span> Dyspnea. <span class="typehead">Skin:</span> Rash, decreased skin sensation. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span>
<b>Adenosine</b> may prolong bradycardia. May increase <b>cyclosporine</b> levels and toxicity. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Rapidly and completely absorbed from GI tract, but only 1524% reaches systemic circulation because of first-pass
      metabolism. <span class="typehead">Onset:</span> 1 h. <span class="typehead">Peak:</span> 23 h. <span class="typehead">Duration:</span> 12 h. <span class="typehead">Distribution:</span> Not known if crosses placenta or is distributed into breast milk. <span class="typehead">Metabolism:</span> Extensive first-pass metabolism in liver. <span class="typehead">Elimination:</span> 70% excreted in urine as inactive metabolites; 30% excreted in feces. <span class="typehead">Half-Life:</span> 511 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor BP throughout course of therapy.</li>
<li>Monitor patients with a history of CHF carefully, especially with concurrent beta blocker use. Promptly report S&amp;S of worsening
            heart failure.
         </li>
<li>Monitor ambulation, especially with older adult patients, until response to drug is known.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Notify physician promptly of shortness of breath, palpitations, or other signs of adverse cardiovascular effects.</li>
<li>Do not drive or engage in other potentially hazardous activities until response to drug is known.</li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>